(5R,6R)-3-(5-azaniumyl-2-methylpentan-2-yl)-6-[(1R)-1-hydroxyethyl]-7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (5R,6R)-3-(5-azaniumyl-2-methylpentan-2-yl)-6-[(1R)-1-hydroxyethyl]-7-oxo-4-oxa-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
• 化学式: C₁₄H₂₂N₂O₅
• 分子量: 298.33
• InChiKey: MJNFEDQKHJZAEX-RGNHYFCHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• Pharmaceutical compositions containing oxapenem-3-carboxylic acids
  申请人：——

  公开号：US20040067929A1

  公开（公告）日：2004-04-08

  An oxapenem compound which is, or is capable of forming, a zwitterion of formula Ia or Ib: (Ia), (Ib) wherein R is a C 1 -C 8 branched or straight chain alkyl group which includes a protonated basic substituent. The compounds find particular use as high bioavailability &bgr;-lactamase inhibitors.

  一种氧杂青霉烷化合物，其为式Ia或Ib的两性离子，或能够形成该两性离子：（Ia），（Ib），其中R为含有质子化碱基取代基的C1-C8支链或直链烷基。该化合物特别适用于高生物利用度β-内酰胺酶抑制剂。
• METHODS OF TREATING BACTERIAL INFECTIONS
  申请人：Rampex Pharmaceuticals, Inc.

  公开号：US20150119363A1

  公开（公告）日：2015-04-30

  The present invention relates to compounds, compositions and methods for treating bacterial infections. Embodiments of the present invention include antibiotics and β-lactamase inhibitors to treat resistant infections.

  本发明涉及用于治疗细菌感染的化合物、组合物和方法。本发明的实施例包括抗生素和β-内酰胺酶抑制剂，以治疗耐药性感染。
• PHARMACEUTICAL COMPOSITIONS CONTAINING OXAPENEM-3-CARBOXILIC ACIDS
  申请人：Amura Limited

  公开号：EP1326607B1

  公开（公告）日：2008-07-23
• STABLE COMPOSITIONS OF OXAPENEM-3-CARBOXYLIC ACIDS BY CO-LYOPHILISATION WITH PHARMACEUTICAL CARRIERS
  申请人：Amura Limited

  公开号：EP1326608B1

  公开（公告）日：2005-12-07
• Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers
  申请人：——

  公开号：US20040043980A1

  公开（公告）日：2004-03-04

  According to the present invention there is provided a pharmaceutical composition comprising a co-lyophilizate of: a pharmaceutical carrier; and an active ingredient of formulae I and II or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 , independently of one another, denote hydrogen, or pharmaceutically acceptable groups which have 1 to 10 carbon atoms and are bonded to the remaining part of the molecule via carbon-carbon single bonds and in which R 3 , R 4 and R 5 , independently of one another, denote pharmaceutically acceptable groups which are bonded to the exocyclic, allylic carbon atom via carbon atoms.